Home > Insider Trading > Filing (0000899243-22-026124)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1274792	Merrimack Pharmaceuticals Inc	MACK	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1548707	Newtyn Partners, Lp	60 East 42Nd Street, 9Th Floor New York NY 10165	No	No	No	Yes
1548709	Newtyn Te Partners, Lp	60 East 42Nd Street, 9Th Floor New York NY 10165	No	No	No	Yes
1569241	Newtyn Management, Llc	60 East 42Nd Street, 9Th Floor New York NY 10165	No	No	No	Yes
1788608	G. Noah Levy	60 East 42Nd Street, 9Th Floor New York NY 10165	Yes	No	No	Yes
1789643	Newtyn Capital Partners, Lp	60 East 42Nd Street, 9Th Floor New York NY 10165	No	No	No	Yes
1789647	Ledo Capital, Llc	60 East 42Nd Street, 9Th Floor New York NY 10165	No	No	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-07-13	3,095	$5.89	754,108	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.60 to $6.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.